Wall Street Analysts Believe Regenxbio (RGNX) Could Rally 95.61%: Here's is How to TradeZacks Investment Research • 11/16/23
REGENXBIO Announces Updated Strategic Plans and Third Quarter 2023 Financial ResultsPRNewsWire • 11/08/23
REGENXBIO Presents Positive One Year Data from Phase II ALTITUDE® Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal DeliveryPRNewsWire • 11/03/23
REGENXBIO to Host Conference Call on November 8 to Discuss Third Quarter 2023 Financial Results and Recent Operational HighlightsPRNewsWire • 11/01/23
REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2023 Annual MeetingPRNewsWire • 10/30/23
REGENXBIO Presents Interim Clinical Data from Phase I/II AFFINITY DUCHENNE™ Trial of RGX-202 at 28th Annual International Congress of the World Muscle SocietyPRNewsWire • 10/03/23
REGENXBIO Announces Presentations at the 28th Annual Congress of the World Muscle SocietyPRNewsWire • 09/26/23
Initial Clinical Data of First Pediatric CLN2 Patient Dosed with RGX-181 Presented at SSIEM Annual SymposiumPRNewsWire • 08/30/23
REGENXBIO Announces Presentations at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023PRNewsWire • 08/23/23
REGENXBIO Reports Second Quarter 2023 Financial Results and Recent Operational HighlightsPRNewsWire • 08/02/23
REGENXBIO Announces Participation at the 2023 Wedbush PacGrow Healthcare ConferencePRNewsWire • 08/01/23
REGENXBIO to Host Conference Call on August 2 to Discuss Second Quarter 2023 Financial Results and Recent Operational HighlightsPRNewsWire • 07/26/23
REGENXBIO Announces Upcoming Presentations at the American Society of Retina Specialists Annual Scientific MeetingPRNewsWire • 07/24/23
REGENXBIO Highlights AAV Pipeline with Interim Results from Retinal and Duchenne Programs at its Virtual Investor Day on July 11, 2023PRNewsWire • 07/11/23
REGENXBIO to Host Virtual Investor Day Highlighting AAV Pipeline Programs with Upcoming Interim Trial UpdatesPRNewsWire • 06/27/23
REGENXBIO and University of Pennsylvania File NAV® Technology Patent Infringement LawsuitPRNewsWire • 06/20/23
Regenxbio could be a gene therapy pioneer with multiple ways to win in 2023Proactive Investors • 06/02/23
REGENXBIO Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RGX-121 Gene Therapy for Hunter SyndromePRNewsWire • 05/23/23